No Laughing Matter 2026 EPK
ELECTRONIC PRESS KIT FOR NO LAUGHING MATTER 2024
ELECTRONIC PRESS KIT FOR NO LAUGHING MATTER 2024
August 18, 2026 - Dr. Mark Souweidane announces the launch of a new opportunity for neurosurgeons to apply for an observership in endoscopic approaches under his mentorship at Weill Cornell Medicine.
June 1, 2026 - Dr. Mark Souweidane co-authored a national consensus study establishing standardized outcome measures for pediatric brain tumor surgery, helping improve research quality and patient care across institutions.
June 1, 2026 - Dr. Mark Souweidane co-authored a national consensus study establishing standardized outcome measures for pediatric brain tumor surgery, helping improve research quality and patient care across institutions.
February 1, 2026 - Weill Cornell Medicine investigators have received a $100,000 grant from the GC Global consortium to study diffuse pediatric brain tumors, including gliomatosis cerebri. The project will develop standardized tools combining imaging and molecular data to better understand how these tumors spread through the brain.
May 28, 2026 - The 2026 Comedy Gala will be held on October 22 at the New York Athletic Club, bringing together 300 distinguished guests in support of pediatric brain tumor research. This year’s gala will honor designer Gretchen Scott for her early and lasting connection to Elizabeth’s Hope and her support of our mission at the CBTP.
May 20, 2026 - Dr. Souweidane was recently invited to present on advances in surgical neurooncology and the field’s shift toward more precise and innovative approaches at 3 national conferences/meetings.
May 14, 2026 -CBTP Program Director Cindy Campbell joined the American Association for Cancer Research (AACR) and colleagues to advocate for sustained federal investment in cancer research. They met with NYS representatives to highlight the importance of continued support for scientific discovery.
APRIL 15, 2026 -Dr. Mark Souweidane has received a grant from The Cure Starts Now Foundation and partners to support a Phase 1a clinical trial testing 177Lu-DTPA-omburtamab in children and young adults with DMG, including DIPG. This next-generation approach combines precision radioimmunotherapy with real-time imaging to evaluate safety, dosing, and drug distribution in the tumor.
MAY 24, 2026 - A new study was published in Cancer Research highlighting how limited genetic ancestral diversity in preclinical models may influence treatment and outcomes in pediatric brain tumor patients. The authors call for more inclusive research systems to ensure future therapies are effective for all children.